Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium pyruvate inhalation in moderate-to-severe COPD (Phase II, China)
CTR20260032Phase 2Active
- Sponsor
- Changtai Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Pyruvic acid in chronic obstructive pulmonary disease (COPD), sponsored by Changtai Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
Pyruvic acid
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20260032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260032.